TGV Sraac Ltd Forensic Report - SOIC x StockScans Report

as of Sep 2026

TGV Sraac's record shows seven consecutive clean audit opinions, but the FY2025-26 annual general meeting asks shareholders to approve a doubling of borrowing powers to ₹1,500 crore and ₹553 crore in new bank facilities for its caustic soda expansion. The company also carries recurring disputed statutory dues across multiple tax statutes and a long-running power dispute flagged by its auditor. Accounting-policy choices have repeatedly shaped reported profit, including a useful-life revision that cut FY2025-26 profit by ₹64.56 crore.

Key findings

  1. Borrowing powers double to ₹1,500 crore with lender equity-conversion rights on default Major - The FY2025-26 AGM notice seeks approval to raise borrowing powers under Section 180(1)(c) from ₹750 crore to ₹1,500 crore for the caustic soda expansion. A consortium of Indian Bank, IDBI Bank, The Federal Bank and The South Indian Bank has sanctioned over ₹553 crore in new facilities, with sanction letters containing a covenant allowing conversion of outstanding loans into equity shares of face value ₹10 each upon default. All debt is secured by pari passu charges over the company's entire fixed assets and undertaking, and personally guaranteed by promoter T.G. Venkatesh.
  2. Recurring disputed statutory dues and a long-running power dispute flagged by the auditor Major - The auditor's CARO report lists disputed statutory dues under income tax, excise, GST, customs, service tax, VAT and entry tax, with periods ranging from 2000-2006 to 2017-18. The FY2022-23 auditor flagged contingent liabilities from ongoing litigation with power distribution companies APSPDCL/APCPDCL as a Key Audit Matter, noting resolution may span multiple years. During FY2022-23, TGV Sraac lodged a ₹47.67 crore claim on APGPCL for power where full credit was not given by APSPDCL, which also raised a demand for the same power.
  3. Accounting-policy choices have repeatedly shaped reported profit Major - During FY2025-26, the company revised the useful life of certain plant and machinery due to obsolescence; had the earlier estimate been retained, depreciation would have been lower by ₹64.56 crore and profit higher by the same amount. In FY2020-21, the company recognised unused brought-forward MAT credit as a deferred tax asset, increasing opening retained earnings by ₹23.71 crore. The company also migrated to new ERP software in FY2025-26, stating it was a change in technological processing, not accounting policies.
  4. Seven clean opinions with two recurring exceptions: audit trail and Bellary land title Major - Brahmayya & Co. issued unqualified opinions for FY2025-26, FY2024-25 and FY2023-24, with no Key Audit Matters reported. However, the accounting software's audit trail was not enabled at database level in FY2025-26, FY2024-25 and FY2023-24, though no tampering was noticed. CARO has reported every year from FY2019-20 through FY2025-26 that title to 12.17 acres of Bellary land, valued at ₹15.29 lakh, was still in the process of being transferred to the company's name.
  5. APGPCL investment written down to nominal value; Brilliant Bio-Pharma stake valued on net assets Minor - The investment in APGPCL is measured at ₹0.10 per share for FY2026, with operations suspended since 2022-23. The FY2023 auditor concluded the methodology and assumptions for valuing the investment at nominal value were appropriate, noting APGPCL had negative profit and huge contingent liabilities. Shares in Brilliant Bio-Pharma Pvt Ltd are valued using the net asset value method, with fixed assets and investments at market value.
  6. Related-party dealings are recurring, shareholder-approved commerce with group company SRHHL Minor - Actual material related-party transactions with Sree Rayalaseema Hi-Strength Hypo Ltd (SRHHL) came to ₹106.90 crore in FY2025-26 against a ₹425 crore omnibus approval. The company states 79% of FY2025-26 related-party transactions were between two listed companies. No loans or advances to promoters, directors or KMPs were reported in FY2025-26.
  7. Revenue recognition is routine, but receivables quality deteriorated sharply in FY22 Minor - The company states it is not reliant on any single external customer, with none providing 10% or more of revenues. Trade receivables jumped to 233.38 crore as at 31 March 2022 from 100.11 crore a year earlier. The FY26 ECL allowance includes an additional provision for doubtful debts beyond the provision-matrix-based amount.
  8. Executive directors aged 72-76 reappointed with special resolutions and Schedule V protection Minor - Sri Karunakar Rao Kamisetty, born 14-06-1950, is proposed for reappointment as Executive Director for three years from 11-05-2027, when he will be 76, requiring a special resolution under Schedule V. Sri Raghavendra Reddy Patil was appointed as Director (Quality Assurance) in FY2025-26 at age 72, also requiring prior approval by special resolution. Shareholder dissent is negligible: resolutions for director appointments received 99.94% votes in favour at the 27-09-2025 AGM.
  9. Auditor rotation occurred on schedule with no resignations or adverse actions Clean - Brahmayya & Co. was appointed as Statutory Auditor for five years from the 40th AGM held 15.09.2022, replacing K.S. Rao & Co. whose term concluded at that AGM. CARO confirms no resignation of statutory auditors during FY2025-26, FY2023-24 and FY2022-23. The secretarial auditor change in FY2023-24 was due to the death of the incumbent on 18.02.2024.

What to watch

Bottom line: This is a disclosed and audited record with orderly auditor governance and shareholder-approved related-party commerce. The risk sits in the expansion financing: a doubled borrowing ceiling, lender conversion rights on default, and personal promoter guarantees. Watch the shareholder vote and the charge registrations, and read the disputed statutory dues and power dispute lines with that context in mind.